Home LiteratureArticle Details
PMID: 40791353 Published · epublish English

Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma.

bioRxiv : the preprint server for biology ·2025-07-17

Murphy A, Liu B, Benton A, Gartenhaus L, Hartzler S, Yates ME, Alzate AR, Janson ND, Jayasundara S, Utturkar S, Lanman NA, Kazemian M, Hanna JA

Abstract

Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of Dicer1, a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting Dgcr8, a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of Dgcr8 phenocopies Dicer1 loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.

Article Info
Journal
bioRxiv : the preprint server for biology
Abbr.
bioRxiv
ISSN
2692-8205
Published
2025-07-17
Language
English
Country/Region
United States
NLM ID
101680187
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]